Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The objective of this study was to identify genetic variants associated with angiotensin-converting enzyme (ACE) inhibitor-associated angioedema. PARTICIPANTS AND METHODS: We carried out a genome-wide association study in 175 individuals with ACE inhibitor-associated angioedema and 489 ACE inhibitor-exposed controls from Nashville (Tennessee) and Marshfield (Wisconsin). We tested for replication in 19 cases and 57 controls who participated in Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET). RESULTS: There were no genome-wide significant associations of any single-nucleotide polymorphism (SNP) with angioedema. Sixteen SNPs in African Americans and 41 SNPs in European Americans were associated moderately with angioedema (P<10) and evaluated for association in ONTARGET. The T allele of rs500766 in PRKCQ was associated with a reduced risk, whereas the G allele of rs2724635 in ETV6 was associated with an increased risk of ACE inhibitor-associated angioedema in the Nashville/Marshfield sample and ONTARGET. In a candidate gene analysis, rs989692 in the gene encoding neprilysin (MME), an enzyme that degrades bradykinin and substance P, was significantly associated with angioedema in ONTARGET and Nashville/Marshfield African Americans. CONCLUSION: Unlike other serious adverse drug effects, ACE inhibitor-associated angioedema is not associated with a variant with a large effect size. Variants in MME and genes involved in immune regulation may be associated with ACE inhibitor-associated angioedema.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07873-x · Cited by 1,380
Angiotensin-Converting Enzyme Inhibitors
Brown, N. J., & Vaughan, D. E. (1998) · Circulation · doi:10.1161/01.cir.97.14.1411 · Cited by 958
Self-citationBrown, N. J., Ray, W. A., Snowden, M., & Griffin, M. R. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90161-7 · Cited by 313
Self-citationIncidence and Characteristics of Angioedema Associated With Enalapril
Kostis, J. B., Kim, H. J., Rusnak, J., Casale, T., Kaplan, A., Corren, J., & Levy, E. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.14.1637 · Cited by 291
Angioedema Incidence in US Veterans Initiating Angiotensin-Converting Enzyme Inhibitors
Miller, D. R., Oliveria, S. A., Berlowitz, D. R., Fincke, B. G., Stang, P., & Lillienfeld, D. E. (2008) · Hypertension · doi:10.1161/hypertensionaha.108.110270 · Cited by 238
Angiotensin-converting enzyme inhibitor-associated angioedema
Byrd, J. B., Adam, A., & Brown, N. J. (2006) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2006.08.001 · Cited by 160
Self-citationDipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema
Byrd, J. B., Touzin, K., Sile, S., Gainer, J. V., Yu, C., Nadeau, J., Adam, A., & Brown, N. J. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.096552 · Cited by 147
Self-citationDuan, Q. L., Nikpoor, B., Dubé, M.-P., Molinaro, G., Meijer, I. A., Dion, P., Rochefort, D., Saint-Onge, J., Flury, L., Brown, N. J., et al. (2005) · The American Journal of Human Genetics · doi:10.1086/496899 · Cited by 126
Self-citationEmanueli, C., Grady, E. F., Madeddu, P., Figini, M., Bunnett, N. W., Parisi, D., Regoli, D., & Geppetti, P. (1998) · Hypertension · doi:10.1161/01.hyp.31.6.1299 · Cited by 114
Woodard-Grice, A. V., Lucisano, A. C., Byrd, J. B., Stone, E. R., Simmons, W. H., & Brown, N. J. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833d3acb · Cited by 92
Self-citationBlais, C., Marc–Aurèle, J., Simmons, W. H., Loute, G., Thibault, P., Skidgel, R. A., & Adam, A. (1999) · Peptides · doi:10.1016/s0196-9781(99)00020-0 · Cited by 60
Cited by
Ghouse, J., Ahlberg, G., Andreasen, L., Banasik, K., Brunak, S., Schwinn, M., Larsen, I. H., Petersen, O., Sørensen, E., Ullum, H., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.05.054 · Cited by 24
Maroteau, C., Siddiqui, M. K., Veluchamy, A., Carr, F., White, M., Cassidy, A. J., Baranova, E. V., Rasmussen, E. R., Eriksson, N., Bloch, K. M., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1927 · Cited by 21
Self-citationMeta-analysis of ACE inhibitor-induced angioedema identifies novel risk locus.
Mathey, C. M., Maj, C., Eriksson, N., Krebs, K., Westmeier, J., David, F. S., Koromina, M., Scheer, A. B., Szabo, N., Wedi, B., et al. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.11.921 · Cited by 15
Metadata
- Authors
- Pare, G., Kubo, M., Byrd, J. B., McCarty, C. A., Woodard-Grice, A., Teo, K. K., Anand, S. S., Zuvich, R. L., Bradford, Y., Ross, S., Nakamura, Y., Ritchie, M., & Brown, N. J.
- Venue
- Pharmacogenetics and Genomics
- Published
- 2013-09
- Volume
- 23
- Issue
- 9
- Pages
- 470-478
- ISSN
- 1744-6872 (ISSN-L)
- OpenAlex
- W2055253331
- Cited by
- 87
- References
- 13
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.